A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Aminoglycosides
/ adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
/ therapeutic use
Calicheamicins
/ adverse effects
Child
DNA
DNA Damage
/ genetics
Gemtuzumab
/ therapeutic use
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Sialic Acid Binding Ig-like Lectin 3
/ metabolism
Transcriptome
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
06
12
2021
accepted:
27
05
2022
revised:
17
05
2022
pubmed:
11
6
2022
medline:
4
8
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we used LASSO regression modeling to develop a 10-gene DNA damage response gene expression score (CalDDR-GEx10) predictive of clinical outcome in pediatric AML patients treated with treatment regimen containing GO from the AAML03P1 and AAML0531 trials (ADE + GO arm, N = 301). When treated with ADE + GO, patients with a high CalDDR-GEx10 score had lower complete remission rates (62.8% vs. 85.5%, P = 1.7 7 * 10
Identifiants
pubmed: 35688939
doi: 10.1038/s41375-022-01622-0
pii: 10.1038/s41375-022-01622-0
pmc: PMC9357169
mid: NIHMS1813919
doi:
Substances chimiques
Aminoglycosides
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Calicheamicins
0
Sialic Acid Binding Ig-like Lectin 3
0
DNA
9007-49-2
Gemtuzumab
93NS566KF7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2022-2031Subventions
Organisme : NCI NIH HHS
ID : R21 CA155524
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
J Clin Oncol. 2014 Sep 20;32(27):3021-32
pubmed: 25092781
Leukemia. 2020 Mar;34(3):735-745
pubmed: 31645648
Future Oncol. 2018 Dec;14(30):3199-3213
pubmed: 30039981
PLoS One. 2013;8(1):e53518
pubmed: 23320091
Bioconjug Chem. 2002 Jan-Feb;13(1):47-58
pubmed: 11792178
J Clin Oncol. 2016 Mar 1;34(7):747-55
pubmed: 26786921
Science. 1988 May 27;240(4856):1198-201
pubmed: 3240341
Clin Oncol (R Coll Radiol). 2014 May;26(5):243-9
pubmed: 24630811
Leuk Lymphoma. 2020 Dec;61(12):2990-2994
pubmed: 32627634
Chem Res Toxicol. 1992 May-Jun;5(3):311-32
pubmed: 1380322
JCO Precis Oncol. 2019 May 23;3:
pubmed: 32914031
J Biol Chem. 2018 Jul 6;293(27):10512-10523
pubmed: 29247009
Annu Rev Biochem. 2010;79:181-211
pubmed: 20192759
Biochemistry. 1993 Apr 13;32(14):3617-22
pubmed: 8466904
Blood Cancer J. 2019 May 21;9(6):51
pubmed: 31113932
Blood. 2003 Jun 1;101(11):4589-97
pubmed: 12576328
DNA Repair (Amst). 2003 Apr 2;2(4):363-74
pubmed: 12606118
Front Oncol. 2020 Feb 13;10:127
pubmed: 32117773
Cancer. 2012 Feb 1;118(3):761-9
pubmed: 21766293
J Clin Oncol. 2017 Aug 10;35(23):2674-2682
pubmed: 28644774
Blood. 1999 Jun 1;93(11):3678-84
pubmed: 10339474
Leuk Lymphoma. 2019 Sep;60(9):2287-2290
pubmed: 30721105
Blood. 2012 Apr 19;119(16):3705-11
pubmed: 22378848
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Clin Cancer Res. 2018 Jul 15;24(14):3242-3246
pubmed: 29476018
Front Immunol. 2021 Aug 16;12:683595
pubmed: 34484181
Oncologist. 2018 Sep;23(9):1103-1108
pubmed: 29650683